MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
8.99
-0.16
-1.75%
After Hours: 8.99 0 0.00% 16:35 03/18 EDT
OPEN
9.00
PREV CLOSE
9.15
HIGH
9.23
LOW
8.88
VOLUME
657.41K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
8.88
MARKET CAP
951.51M
P/E (TTM)
-2.8621
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RCUS last week (0310-0314)?
Weekly Report · 2d ago
Weekly Report: what happened at RCUS last week (0303-0307)?
Weekly Report · 03/10 09:20
Little Excitement Around Arcus Biosciences, Inc.'s (NYSE:RCUS) Revenues As Shares Take 26% Pounding
Simply Wall St · 03/06 10:26
Morgan Stanley Remains a Buy on Arcus Biosciences (RCUS)
TipRanks · 03/03 13:06
Weekly Report: what happened at RCUS last week (0224-0228)?
Weekly Report · 03/03 09:20
Insider Purchase: Director at $RCUS Buys 20,000 Shares
NASDAQ · 02/28 00:15
Arcus Biosciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St · 02/27 10:21
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Certara (CERT)
TipRanks · 02/27 09:30
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.